1-[4-(aminosulfonyl)phenyl]-5-phenyl-1H-pyrazole-3-carboxylic acid methyl ester | 170570-83-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-[4-(aminosulfonyl)phenyl]-5-phenyl-1H-pyrazole-3-carboxylic acid methyl ester
• 英文别名: (4-(aminosulfonyl)phenyl)-5-phenyl-1H-pyrazole-3-carboxylic acid methyl ester；methyl 1-[(4-aminosulfonyl)phenyl]-5-phenyl-1H-pyrazole-3-carboxylate；Methyl 1-[(4-Aminosulfonyl)phenyl]-5-phenyl-1H-pyrazol-3-Carboxylate；Methyl-5-phenyl-1-(4-sulfamoylphenyl)-1H-pyrazole-3-carboxylate；Methyl 5-phenyl-1-(4-sulfamoylphenyl)pyrazole-3-carboxylate
• CAS: 170570-83-9
• 化学式: C₁₇H₁₅N₃O₄S
• 分子量: 357.39
• InChiKey: DXTMFEDDQSOXIB-UHFFFAOYSA-N

物化性质

• 沸点：
  588.3±60.0 °C(Predicted)
• 密度：
  1.39±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  25
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  113
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  1-[4-(aminosulfonyl)phenyl]-5-phenyl-1H-pyrazole-3-carboxylic acid methyl ester 在 水 、 potassium hydroxide 作用下， 以 甲醇 为溶剂， 反应 3.0h， 生成 1-(p-sulfamylphenyl)-5-phenylpyrazole-3-carboxylic acid
  参考文献：
  名称：

  吡唑和香豆素作为COX-2和5-LOX双重抑制剂的新型杂化物的合成

  摘要：

  在我们先前的研究中，我们设计了一系列吡唑衍生物作为新型COX-2抑制剂。为了获得新型的COX-2和5-LOX双重抑制剂，我们在此设计并合成了20种化合物，方法是将吡唑与取代的香豆素杂交，据报道，该香豆素具有5-LOX抑制作用，并使用包括选择性抑制在内的充分生物学试验依次选择有效的化合物。 COX-2和5-LOX的表达，体外抗增殖，细胞凋亡和细胞周期。其中，最有效的化合物11g（ COX-2的IC 50 = 0.23±  0.16μM，5-LOX的IC 50 = 0.87±0.07μM， 针对A549的IC 50 = 4.48±0.57μM）与阳性对照相比具有初步优势。控制塞来昔布（ 对于COX-2，IC 50 = 0.41± 0.28μM， 对于A549 ，IC 50 = 7.68± 0.55μM）和Zileuton（ 对于5-LOX，IC 50 = 1.35± 0.24μM）。进一步的研

  DOI：

  10.1016/j.bmcl.2017.07.020
• 作为产物：
  描述：

  苯乙酮 在 sodium methylate 作用下， 以 甲醇 为溶剂， 反应 12.17h， 生成 1-[4-(aminosulfonyl)phenyl]-5-phenyl-1H-pyrazole-3-carboxylic acid methyl ester
  参考文献：
  名称：

  香豆素磺酰胺衍生物作为有效的和选择性的COX-2抑制剂，具有抑制癌症增殖和转移的功效

  摘要：

  环氧合酶2在恶性肿瘤中经常过度表达，产物PGE 2促进癌细胞的发展和转移。我们设计了一系列香豆素磺酰胺衍生物，以改善COX-2抑制和抗癌的生物活性。其中，化合物7吨表明最强大的选择性的抑制和抗增殖活性（IC 50  = 0.09μM为COX-2，IC 50  = 48.20μM为COX-1，IC 50  = 0.36μM对HeLa细胞），具有可比性到控制正化合物塞来昔布（0.31μM，43.37μM，7.79μM）。进行癌细胞凋亡测定，结果表明化合物7t以剂量和时间依赖性有效地促进HeLa细胞凋亡。此外，7t可以显着抑制癌细胞的粘附，迁移和侵袭，这是癌症转移的重要过程。对接模拟结果进一步表明，化合物7t可以很好地与COX-2活性位点结合，并在将来指导合理设计具有抗癌活性的选择性COX-2抑制剂。

  DOI：

  10.1016/j.bmcl.2016.06.037

文献信息

• Design, synthesis and evaluation of benzenesulfonamide-substituted 1,5-diarylpyrazoles containing phenylacetohydrazide derivatives as COX-1/COX-2 agents against solid tumors
  作者：Xiao-Yuan Lu、Zhong-Chang Wang、Ting Wei、Xiao-Qiang Yan、Peng-Fei Wang、Hai-Liang Zhu

  DOI：10.1039/c6ra02168a

  日期：——

  phenylacetohydrazide derivatives have been designed, synthesized and evaluated for their biological activities as selective COX-2 inhibitors with anticancer potential. In vitro the bioassay results revealed that some of them displayed potent inhibitory activity in the enzymatic and cellular assays. Among them, compound 48 showed the most powerful and potent selective inhibitory activity (IC50 = 82.21 μM

  已经设计，合成并评估了新型的含苯乙酰肼衍生物的苯磺酰胺取代的1,5-二芳基吡唑类化合物作为具有抗癌潜力的选择性COX-2抑制剂的生物活性。在体外，生物测定结果表明，其中一些在酶和细胞测定中显示出有效的抑制活性。其中，化合物48显示出最有力和有效的选择性的抑制活性（IC 50 = 82.21μM为COX-1和IC 50 = 0.37μM为COX-2），相媲美的控制正化合物塞来考昔（40.29μM，0.15μM） 。抗增殖试验结果表明该化合物48在体外对A549细胞具有强大的抗增殖活性，IC 50值为0.78μM。然后，我们对化合物48进行了PI染色测定和细胞凋亡分析，发现其有效引起A549细胞凋亡。进一步进行对接模拟以将化合物48定位在COX-2活性位点中以确定可能的结合模型。建立3D-QSAR模型是为了将来合理设计选择性COX-2抑制剂。
• Towards safer anti-inflammatory therapy: synthesis of new thymol–pyrazole hybrids as dual COX-2/5-LOX inhibitors
  作者：Mostafa M. M. El-Miligy、Ahmed K. Al-Kubeisi、Mohamed G. Bekhit、Saad R. El-Zemity、Rasha A. Nassra、Aly A. Hazzaa

  DOI：10.1080/14756366.2022.2147164

  日期：2023.1.1

  Abstract New thymol − 1,5-disubstitutedpyrazole hybrids were synthesised as dual COX-2/5-LOX inhibitors. Compounds 8b, 8g, 8c, and 4a displayed in vitro inhibitory activity against COX-2 (IC50 = 0.043, 0.045, 0.063, and 0.068 µM) nearly equal to celecoxib (IC50 = 0.045 µM) with high SI (316, 268, 204, and 151, respectively) comparable to celecoxib (327). All target compounds, 4a–c and 8a–i, showed

  摘要 新的百里酚 − 1,5-二取代吡唑杂化物被合成为双重 COX-2/5-LOX 抑制剂。化合物8b、8g、8c和4a对 COX-2的体外抑制活性（IC 50  = 0.043、0.045、0.063和 0.068 µM ）几乎等于塞来昔布（IC 50  = 0.045 µM ），具有高 SI（316、268 ） 、204 和 151）与塞来昔布 (327) 相当。所有目标化合物4a–c和8a–i均显示出高于参考槲皮素的体外5-LOX 抑制活性。此外，他们还拥有体内对福尔马林引起的爪水肿的抑制作用高于塞来昔布。此外，化合物4a、4b、8b和8g在禁食大鼠群体中表现出优于塞来昔布和双氯芬酸钠的胃肠道安全性特征（无溃疡）。总之，化合物4a、8b和8g达到了目标。它们在体外引起比塞来昔布和槲皮素更高的 COX-2/5-LOX 双重抑制，比塞来昔布更高的体内抗炎活性和比塞来昔布更高的体内胃肠道安全性（无溃疡）。
• Synthesis and Biological Evaluation of the 1,5-Diarylpyrazole Class of Cyclooxygenase-2 Inhibitors:  Identification of 4-[5-(4-Methylphenyl)-3- (trifluoromethyl)-1<i>H</i>-pyrazol-1-yl]benzenesulfonamide (SC-58635, Celecoxib)
  作者：Thomas D. Penning、John J. Talley、Stephen R. Bertenshaw、Jeffery S. Carter、Paul W. Collins、Stephen Docter、Matthew J. Graneto、Len F. Lee、James W. Malecha、Julie M. Miyashiro、Roland S. Rogers、D. J. Rogier、Stella S. Yu、Gary D. Anderson、Earl G. Burton、J. Nita Cogburn、Susan A. Gregory、Carol M. Koboldt、William E. Perkins、Karen Seibert、Amy W. Veenhuizen、Yan Y. Zhang、Peter C. Isakson

  DOI：10.1021/jm960803q

  日期：1997.4.1

  A series of sulfonamide-containing 1,5-diarylpyrazole derivatives were prepared and evaluated for their ability to block cyclooxygenase-2 (COX-2) in vitro and in vivo. Extensive structure-activity relationship (SAR) work was carried out within this series, and a number of potent and selective inhibitors of COX-2 were identified. Since an early structural lead (1f, SC-236) exhibited an unacceptably long plasma half-life, a number of pyrazole analogs containing potential metabolic sites were evaluated further in vivo in an effort to identify compounds with acceptable pharmacokinetic profiles. This work led to the identification of ii (4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide, SC-58635, celecoxib), which is currently in phase III clinical trials for the treatment of rheumatoid arthritis and osteoarthritis.
• Design, synthesis and evaluation of novel diaryl-1,5-diazoles derivatives bearing morpholine as potent dual COX-2/5-LOX inhibitors and antitumor agents
  作者：Zhang Li、Zhong-Chang Wang、Xin Li、Muhammad Abbas、Song-Yu Wu、Shen-Zhen Ren、Qi-Xing Liu、Yi Liu、Peng-Wen Chen、Yong-Tao Duan、Peng-Cheng Lv、Hai-Liang Zhu

  DOI：10.1016/j.ejmech.2019.03.008

  日期：2019.5

  In this paper, 41 hybrid compounds containing diaryl-1,5-diazole and morpholine structures acting as dual COX-2/5-LOX inhibitors have been designed, synthesized and biologically evaluated. Most of them showed potent antiproliferative activities and COX-2/5-LOX inhibitory in vitro. Among them, compound A33 displayed the most potency against cancer cell lines (IC50 = 6.43-10.97 mu M for F10, HeLa, A549 and MCF-7 cells), lower toxicity to non-cancer cells than celecoxib (A33: IC50 = 194.01 mu M vs. celecoxib: IC50 = 97.87 mu M for 293T cells), and excellent inhibitory activities on COX-2 (IC50 = 0.17 mu M) and 5-LOX (IC50 = 0.68 mu M). Meanwhile, the molecular modeling study was performed to position compound A33 into COX-2 and 5-LOX active sites to determine the probable binding models. Mechanistic studies demonstrated that compound A33 could block cell cycle in G2 phase and subsequently induced apoptosis of F10 cells. Furthermore, compound A33 could significantly inhibit tumor growth in F10-xenograft mouse model, and pharmacokinetic study of compound A33 indicated that it showed better stability in vivo. in general, compound A33 could be a promising candidate for cancer therapy. (C) 2019 Elsevier Masson SAS. All rights reserved.
• US6716991B1
  申请人：——

  公开号：US6716991B1

  公开（公告）日：2004-04-06